Reinfection rates of hepatitis C virus (HCV) following treatment with direct-acting antivirals (DAA) were assessed in a large, population-based cohort study presented at The Liver Meeting 2018.
In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included 1.7 million people that were tested for HCV. “We assessed HCV-infected individuals treated with DAAs between 1/1/2014 and 7/1/2017 who achieved SVR and had ≥1 subsequent HCV RNA test for reinfection,” the study authors explained. Reinfection was defined as one positive HCV RNA test following SVR and persistent reinfections were considered in patients who did not spontaneously clear.
An algorithm derived from physician diagnosis and hospitalization codes was utilized to assess current (3 years prior to SVR) and former (≥3 years prior to SVR) PWID. The study authors stated, “Crude reinfection rates per